CN102099376A - 针对her2的细胞外结构域2和3的抗体 - Google Patents

针对her2的细胞外结构域2和3的抗体 Download PDF

Info

Publication number
CN102099376A
CN102099376A CN2008801297639A CN200880129763A CN102099376A CN 102099376 A CN102099376 A CN 102099376A CN 2008801297639 A CN2008801297639 A CN 2008801297639A CN 200880129763 A CN200880129763 A CN 200880129763A CN 102099376 A CN102099376 A CN 102099376A
Authority
CN
China
Prior art keywords
affinity ligand
cancer
her2
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801297639A
Other languages
English (en)
Chinese (zh)
Inventor
M·乌莱恩
J·罗克伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Publication of CN102099376A publication Critical patent/CN102099376A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2008801297639A 2008-06-13 2008-12-12 针对her2的细胞外结构域2和3的抗体 Pending CN102099376A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008155676A JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット
JP2008-155676 2008-06-13
US7635208P 2008-06-27 2008-06-27
US61/076352 2008-06-27
PCT/SE2008/000694 WO2009151356A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2

Publications (1)

Publication Number Publication Date
CN102099376A true CN102099376A (zh) 2011-06-15

Family

ID=40427661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801297639A Pending CN102099376A (zh) 2008-06-13 2008-12-12 针对her2的细胞外结构域2和3的抗体

Country Status (8)

Country Link
US (1) US20110158988A1 (enExample)
EP (1) EP2294088A1 (enExample)
JP (1) JP2010006705A (enExample)
KR (2) KR20130026418A (enExample)
CN (1) CN102099376A (enExample)
AU (1) AU2008357729A1 (enExample)
CA (1) CA2727941A1 (enExample)
WO (1) WO2009151356A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017425A (zh) * 2014-04-30 2015-11-04 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
CN111670201A (zh) * 2019-03-01 2020-09-15 荣昌生物制药(烟台)股份有限公司 一种Her2伴随诊断免疫组化检测抗体及其应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101759209B1 (ko) 2010-01-22 2017-07-19 성균관대학교산학협력단 Ｈｅｒ－２ 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
AU2016201799B2 (en) * 2010-05-27 2017-09-07 Genmab A/S Monoclonal antibodies aganst HER2 epitope
CA3051311A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) * 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
JP6971319B2 (ja) 2016-12-28 2021-11-24 グリーン・クロス・ラブ・セル・コーポレイション キメラ抗原受容体及びそれを発現するナチュラルキラー細胞
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
AU2018383096A1 (en) * 2017-12-11 2020-06-11 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
WO2020036869A1 (en) 2018-08-16 2020-02-20 Emd Millipore Corporation Closed bioprocessing device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
CN101023100A (zh) * 2004-07-22 2007-08-22 健泰科生物技术公司 Her2抗体组合物
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
CN101165068A (zh) * 2006-10-18 2008-04-23 上海复旦张江生物医药股份有限公司 抗HER2/ErbB2抗原的单克隆抗体及其制备方法和药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1136917C (zh) * 2001-10-10 2004-02-04 北京迪威华宇生物技术有限公司 一种卡介苗热休克蛋白65和多表位her-2抗原融合蛋白重组蛋白疫苗
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ES2348312T3 (es) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
CN101023100A (zh) * 2004-07-22 2007-08-22 健泰科生物技术公司 Her2抗体组合物
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
CN101165068A (zh) * 2006-10-18 2008-04-23 上海复旦张江生物医药股份有限公司 抗HER2/ErbB2抗原的单克隆抗体及其制备方法和药物组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017425A (zh) * 2014-04-30 2015-11-04 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
WO2015165368A1 (zh) * 2014-04-30 2015-11-05 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
CN105017425B (zh) * 2014-04-30 2018-02-16 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
CN111670201A (zh) * 2019-03-01 2020-09-15 荣昌生物制药(烟台)股份有限公司 一种Her2伴随诊断免疫组化检测抗体及其应用

Also Published As

Publication number Publication date
WO2009151356A1 (en) 2009-12-17
AU2008357729A8 (en) 2011-02-03
US20110158988A1 (en) 2011-06-30
CA2727941A1 (en) 2009-12-17
AU2008357729A1 (en) 2009-12-17
KR20110036534A (ko) 2011-04-07
JP2010006705A (ja) 2010-01-14
KR20130026418A (ko) 2013-03-13
EP2294088A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
CN102099376A (zh) 针对her2的细胞外结构域2和3的抗体
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
AU2012315792B2 (en) Therapeutic peptides
JP7209464B2 (ja) ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体
AU2016340764A1 (en) Binding molecules that inhibit cancer growth
JP2024167313A (ja) 腫瘍治療薬及びその応用
KR20140107615A (ko) 엑소좀 검출용 모노클로날 항체
MX2012011234A (es) Anticuerpos contra csf-1r.
CN110177571B (zh) 工程化抗体及其用途
Kim et al. Generation of a human antibody that inhibits TSPAN8-mediated invasion of metastatic colorectal cancer cells
EP4069372A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN112812179B (zh) 高亲和力高特异性抗cmtm6单克隆抗体及其用途
CN112823168A (zh) 结合her2的四聚体多肽
TW202330626A (zh) 雙特異性抗體及其應用
WO2023011614A1 (zh) 抗pd-l1纳米抗体及其应用
CN117715940A (zh) 抗trem-1抗体
HK40051469A (en) Her2-binding tetrameric polypeptides
CN118829657A (zh) 多特异性抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110615